Gossamer Bio, Inc. 8-K

What Happened
Gossamer Bio, Inc. (GOSS) filed an 8-K reporting the results of its June 4, 2026 annual meeting of stockholders (filed June 5, 2026). Two Class II directors — Faheem Hasnain and Russell Cox — were re-elected to three‑year terms expiring at the 2029 annual meeting. Shareholders also ratified the selection of Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal year 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers.

Key Details

• Faheem Hasnain re-elected as Class II director for a term expiring 2029: For 92,301,637; Withheld 26,667,876; Broker non-votes 45,450,098.
• Russell Cox re-elected as Class II director for a term expiring 2029: For 88,975,980; Withheld 29,993,533; Broker non-votes 45,450,098.
• Ernst & Young LLP ratified as independent auditor for FY2026: For 163,185,993; Against 1,192,448; Abstain 41,170.
• Advisory approval of named executive officer compensation: For 111,286,550; Against 7,545,502; Abstain 137,461; Broker non-votes 45,450,098.

Why It Matters
These outcomes confirm board continuity (two directors re-elected) and shareholder support for the company’s choice of auditor (Ernst & Young), which affects financial reporting oversight. The advisory "say-on-pay" passed, indicating majority shareholder approval of executive compensation, though it is non-binding. The presence of substantial broker non-votes on several matters (45.45M) shows a material number of shares were not voted by brokers, which can affect the vote totals on non-routine items.